Welcome to our dedicated page for Pheton Holdings SEC filings (Ticker: PTHL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Brachytherapy planning isn’t just technically demanding—it’s capital intensive. When investors ask, “Where does Pheton Holdings spend its R&D budget?” or “How do pending FDA reviews affect cash flow?”, the answers live inside the company’s SEC filings. Stock Titan gathers every 10-K, 10-Q, 8-K material event, and Pheton Holdings insider trading Form 4 transactions the moment they hit EDGAR, so you don’t have to sift through multiple sources.
Navigate straight to the details you search for most: the Pheton Holdings quarterly earnings report 10-Q filing that breaks out software licensing revenue, the proxy statement that lists executive compensation tied to FTTPS milestones, or the 8-K that flags trial-site expansions. Our AI-powered summaries translate dense technical language—“organs at risk dose constraints” or “510(k) submission timelines”—into plain English, making understanding Pheton Holdings SEC documents with AI both fast and accurate. Need alerts on Pheton Holdings Form 4 insider transactions real-time? They’re delivered instantly so you can monitor management’s confidence before key announcements.
Whether you’re tracking development costs hidden deep in an annual report, comparing quarter-over-quarter licensing growth, or checking a Pheton Holdings executive stock transactions Form 4, every filing is searchable, summarized, and linked to original pages. Investors use these insights to gauge regulatory risk, validate revenue projections, and spot emerging trends in radiation oncology. Stock Titan turns a 250-page Pheton Holdings annual report 10-K simplified into actionable insight—so you can focus on decisions, not document hunting.
Theia Investment Holding (BVI) LTD and its director Xiaobing Dai filed Amendment No. 1 to Schedule 13G for Pheton Holdings Ltd (PTHL) covering the event date 05 May 2025. The filing states that the reporting persons now own 0 Class A ordinary shares, giving them 0 % of the outstanding class. All voting and dispositive power—sole or shared—is listed as 0. The amendment is triggered because their ownership has fallen below the 5 % reporting threshold.
Theia Investment Holding is incorporated in the British Virgin Islands; Dai is a PRC citizen and serves as the entity’s director. A joint-filing agreement (Ex. 99.1) is referenced, but no other economic arrangements or transactions are disclosed. The certification section affirms the accuracy of the information.
Key takeaway: a previously reportable shareholder has fully exited its stake, potentially increasing PTHL’s public float and removing a source of concentrated ownership.
Theia Investment Holding (BVI) LTD and its director Xiaobing Dai filed Amendment No. 1 to Schedule 13G for Pheton Holdings Ltd (PTHL) covering the event date 05 May 2025. The filing states that the reporting persons now own 0 Class A ordinary shares, giving them 0 % of the outstanding class. All voting and dispositive power—sole or shared—is listed as 0. The amendment is triggered because their ownership has fallen below the 5 % reporting threshold.
Theia Investment Holding is incorporated in the British Virgin Islands; Dai is a PRC citizen and serves as the entity’s director. A joint-filing agreement (Ex. 99.1) is referenced, but no other economic arrangements or transactions are disclosed. The certification section affirms the accuracy of the information.
Key takeaway: a previously reportable shareholder has fully exited its stake, potentially increasing PTHL’s public float and removing a source of concentrated ownership.
Theia Investment Holding (BVI) LTD and its director Xiaobing Dai filed Amendment No. 1 to Schedule 13G for Pheton Holdings Ltd (PTHL) covering the event date 05 May 2025. The filing states that the reporting persons now own 0 Class A ordinary shares, giving them 0 % of the outstanding class. All voting and dispositive power—sole or shared—is listed as 0. The amendment is triggered because their ownership has fallen below the 5 % reporting threshold.
Theia Investment Holding is incorporated in the British Virgin Islands; Dai is a PRC citizen and serves as the entity’s director. A joint-filing agreement (Ex. 99.1) is referenced, but no other economic arrangements or transactions are disclosed. The certification section affirms the accuracy of the information.
Key takeaway: a previously reportable shareholder has fully exited its stake, potentially increasing PTHL’s public float and removing a source of concentrated ownership.
Quad/Graphics (Q2 25 10-Q): Net sales fell 9.8% YoY to $571.9 m as product sales declined 10% and services 9%. Gross profit slipped to $123.8 m (21.6% margin), yet tight cost control kept operating income at $13.7 m (2.4% margin, –9% YoY). Interest expense dropped 23% to $13.2 m, resulting in essentially breakeven EPS ($0.00 vs -$0.06). Six-month figures show a sharper turnaround: sales –6.8% to $1.20 bn but operating income up 7.5× to $33.3 m; net earnings swung to $5.7 m profit (EPS $0.12) from a $30.9 m loss.
Liquidity & leverage: Cash fell to $6.7 m (vs $29.2 m YE) after -$41.6 m operating cash outflow and $38.2 m investing spend, including $27 m for Enru assets. Long-term debt rose to $420.5 m, but total liabilities declined 7.6% to $1.15 bn; equity improved to $87.0 m on OCI gains. Revolver usage remains active; leverage covenants were amended in Oct-24.
Strategic moves: 1) Acquired Enru co-mail assets to expand logistics platform. 2) Divested European operations for $24.1 m (note receivable) with a $0.5 m loss, lowering international exposure. 3) Restructuring/impairment charges dropped to $15.8 m YTD (-63%), supporting margin recovery. Capital returns resumed: $7.6 m buybacks & $0.075/sh quarterly dividend.
Quad/Graphics (Q2 25 10-Q): Net sales fell 9.8% YoY to $571.9 m as product sales declined 10% and services 9%. Gross profit slipped to $123.8 m (21.6% margin), yet tight cost control kept operating income at $13.7 m (2.4% margin, –9% YoY). Interest expense dropped 23% to $13.2 m, resulting in essentially breakeven EPS ($0.00 vs -$0.06). Six-month figures show a sharper turnaround: sales –6.8% to $1.20 bn but operating income up 7.5× to $33.3 m; net earnings swung to $5.7 m profit (EPS $0.12) from a $30.9 m loss.
Liquidity & leverage: Cash fell to $6.7 m (vs $29.2 m YE) after -$41.6 m operating cash outflow and $38.2 m investing spend, including $27 m for Enru assets. Long-term debt rose to $420.5 m, but total liabilities declined 7.6% to $1.15 bn; equity improved to $87.0 m on OCI gains. Revolver usage remains active; leverage covenants were amended in Oct-24.
Strategic moves: 1) Acquired Enru co-mail assets to expand logistics platform. 2) Divested European operations for $24.1 m (note receivable) with a $0.5 m loss, lowering international exposure. 3) Restructuring/impairment charges dropped to $15.8 m YTD (-63%), supporting margin recovery. Capital returns resumed: $7.6 m buybacks & $0.075/sh quarterly dividend.
Quad/Graphics (Q2 25 10-Q): Net sales fell 9.8% YoY to $571.9 m as product sales declined 10% and services 9%. Gross profit slipped to $123.8 m (21.6% margin), yet tight cost control kept operating income at $13.7 m (2.4% margin, –9% YoY). Interest expense dropped 23% to $13.2 m, resulting in essentially breakeven EPS ($0.00 vs -$0.06). Six-month figures show a sharper turnaround: sales –6.8% to $1.20 bn but operating income up 7.5× to $33.3 m; net earnings swung to $5.7 m profit (EPS $0.12) from a $30.9 m loss.
Liquidity & leverage: Cash fell to $6.7 m (vs $29.2 m YE) after -$41.6 m operating cash outflow and $38.2 m investing spend, including $27 m for Enru assets. Long-term debt rose to $420.5 m, but total liabilities declined 7.6% to $1.15 bn; equity improved to $87.0 m on OCI gains. Revolver usage remains active; leverage covenants were amended in Oct-24.
Strategic moves: 1) Acquired Enru co-mail assets to expand logistics platform. 2) Divested European operations for $24.1 m (note receivable) with a $0.5 m loss, lowering international exposure. 3) Restructuring/impairment charges dropped to $15.8 m YTD (-63%), supporting margin recovery. Capital returns resumed: $7.6 m buybacks & $0.075/sh quarterly dividend.
FAQ
What is the current stock price of Pheton Holdings (PTHL)?
What is the market cap of Pheton Holdings (PTHL)?
What is the primary focus of Pheton Holdings Ltd?
How does the FTTPS system benefit cancer treatment?
Which sector of the healthcare industry does Pheton Holdings operate in?
How does Pheton Holdings integrate clinical expertise into its technology?
What makes Pheton Holdings' approach unique in the brachytherapy field?
How does the company support safety in its treatment planning processes?
